Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer

doi:10.3748/wjg.v26.i8.804

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8918)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series.

Item

Count

PDF

593

WORD

146

HTML

5913

Figures (1-7)

354

Sum=7006

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

820

Download

1092

Sum=1912

Feb 28, 2020 (publication date) through Feb 7, 2025

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Feb 28, 2020; 26(8): 804-817
Published online Feb 28, 2020. doi: 10.3748/wjg.v26.i8.804

Full Size Figure Download Figure

Figure 2 ORMs are downregulated in liver tumor tissues. A and B: The different The Cancer Genome Atlas cancer databases were analyzed for orosomucoid 1 (ORM1) (A) and ORM2 (B) expression level differences between tumor and adjacent normal tissues. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs normal tissues, respectively. ACC: Adrenocortical carcinoma; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; DLBC: Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LAML: Acute myeloid leukemia; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OV: Ovarian serous cystadenocarcinoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and Paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SKCM: Skin cutaneous melanoma; STAD: Stomach adenocarcinoma; TGCT: Testicular germ cell tumors; THCA: Thyroid carcinoma; THYM: Thymoma; UCEC: Uterine corpus endometrial carcinoma; UCS: Uterine carcinosarcoma; UVM: Uveal melanoma.

Citation: Zhu HZ, Zhou WJ, Wan YF, Ge K, Lu J, Jia CK. Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer. World J Gastroenterol 2020; 26(8): 804-817
URL: https://www.wjgnet.com/1007-9327/full/v26/i8/804.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i8.804